I have been following this company from NZ for a year or so now. Seems they might be onto something.

"6
June 2017
–
Sydney, Australia & Auckland, New Zealand
–
130 weeks
after treatment a
ll
four patients who took part in
Living Cell Technologies
Limited’s
Phase I/IIa clinical study of NTCELL
®
for Parkinson’s disease
remain well and
there are no safety concerns. The primary clinical endpoint of
this initial open clinical study
,
involving the implantation of 40 NTCELL capsules
into the putamen on
one side of the brain only, is safety. "

Here is a link to the full press release (PDF), which contains a bit more information:

http://www.lctglobal.com/upload/news...30%20weeks.pdf